Seed funding for medtech start-up EVERSION

EVERSION secures seven-figure seed funding. With a sensor insole and app, the start-up offers a data-supported solution for pain reduction and preventive health measures.

Constance, January 22, 2025 - The medtech startup EVERSION from Constance has raised a seven-figure sum in a successful seed financing round. With this financial support, the young company will be able to further develop its solution for reducing musculoskeletal complaints and bring it to market. The Chancenkapitalfonds of Kreissparkasse Biberach is leading this round as lead investor, accompanied by investors such as the Berlin Angel Fund and the Angels4Health investors. EVERSION not only impresses with its technology, but also with a strong network of business angels and experts from the fields of medicine, technology and marketing/sales.

Customizable insoles

EVERSION's main product is aimed at people with musculoskeletal complaints who are often looking for solutions to reduce pain. The company offers an innovative solution in the form of sensor insoles and an accompanying app that enable long-term gait analysis in everyday life. The data is used to identify precise causes of pain and create customized insoles on this basis. These insoles are no ordinary orthopaedic insoles, but a new development that mobilizes the foot in everyday life and compensates for misalignments.

Companies as partners in occupational health management (OHM)

In addition to the end customer group, EVERSION also appeals to companies that want to use the solutions as part of their occupational health management (OHM). By using the insoles preventively, companies can not only promote the health of their employees, but also actively reduce absenteeism and sick days. These partnership opportunities expand the market for EVERSION and enable a broader distribution of the products.

Strong support from investors and business angels

EVERSION's new investors include digital health expert Thilo Veil, who was named "Berlin Business Angel of the Year 2024", as well as experienced personalities from the medical and corporate world, including Dr. Melanie Pars and Dr. Bettina Volkens. The EVERSION team can look forward to valuable networks and expertise to ensure the company's continued success. The financing round was oversubscribed, reflecting the confidence in the company and the technology.

Market entry and further product development

With the financing secured, EVERSION will reach the next milestones, including product development and market entry. An important step in this process is the approval of the insoles as a medical product. Interested end customers can already put their names on the waiting list for the product launch, while companies interested in collaborations in the field of BGM will be invited to discuss possible pilot projects.